Twist Bioscience Corp
For the period ended Dec 31, 2025. Filed Feb 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
| Three months ended December 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Operating activities | ||
| Net loss | $(30,507) | $(31,594) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 6,194 | 6,380 |
| Stock-based compensation expense | 13,273 | 11,991 |
| Other non-cash adjustments[1] | (336) | (20) |
| Changes in assets and liabilities: | ||
| Accounts receivable, net [2] | 6,826 | (4,537) |
| Inventories | (4,615) | 560 |
| Prepaid expenses and other current assets [3] | (7,735) | (249) |
| Other non-current assets | 225 | (356) |
| Accounts payable | 1,472 | 5,711 |
| Accrued expenses | 1,509 | 3,137 |
| Accrued compensation | (12,436) | (11,850) |
| Other liabilities | 1,316 | (601) |
| Net cash used in operating activities | $(24,814) | $(21,428) |
| Investing activities | ||
| Purchases of property and equipment | $(9,974) | $(2,268) |
| Purchases of investments | (20,509) | (20,593) |
| Proceeds from maturity of investments | 20,550 | 21,325 |
| Net cash used in investing activities | $(9,933) | $(1,536) |
| Financing activities | ||
| Proceeds from exercise of stock options | $300 | $2,950 |
| Proceeds from the issuance of liability related to sale of future revenue | — | 15,000 |
| Repurchases of common stock for income tax withholding | (2) | (6) |
| Net cash provided by financing activities | $298 | $17,944 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | $9 | $(53) |
| Net decrease in cash, cash equivalents, and restricted cash | (34,440) | (5,073) |
| Cash, cash equivalents, and restricted cash at beginning of period | 185,425 | 229,132 |
| Cash, cash equivalents, and restricted cash at end of period | $150,985 | $224,059 |
| Supplemental disclosure of cash flow information | ||
| Income taxes paid, net of refunds | $184 | $3 |
| Non-cash investing and financing activities | ||
| Property and equipment additions included in accounts payable and accrued expenses | $1,182 | $2,136 |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $24,773 | $— |
[1]Including changes in a related party' balances of $0.1 million and $— million for the three months ended December 31, 2025 and December 31, 2024, respectively.
[2] Including changes in the related parties' balances of $— million and $(0.2) million for the three months ended December 31, 2025 and December 31, 2024, respectively.
[3]Including changes in a related party balances of $0.3 million and $— million for the three months ended December 31, 2025 and December 31, 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.